Gait Analysis in MPS IVA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01920828|
Recruitment Status : Completed
First Posted : August 12, 2013
Last Update Posted : October 17, 2019
|Condition or disease|
|MPS IVA Morquio Syndrome|
The purpose of this 3-year study is to conduct a longitudinal investigation using motion analysis of gait to objectively and quantitatively assess gait characteristics of MPS IVA patients. Data documenting gait characteristics and abnormalities will be gathered in patients initiating enzyme replacement therapy.
Inclusion criteria Individuals with MPS IVA diagnosed by enzyme or molecular studies Exclusion Criteria Individual with MPS IVA previously enrolled in BMN-110 Individual is non-ambulatory The individual is unable to complete longitudinal study visits at least yearly
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Gait Analysis in Patients With MPS IVA Treated With Enzyme Replacement Therapy|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||June 2017|
|Actual Study Completion Date :||June 2017|
- Measurable changes in gait [ Time Frame: 36 months ]Data acquired on patients will be compared with age-matched standardized norms. The normal data is available from a pre-existing Gait Repository, a collection of gait parameters in children without a specific diagnosis studied at Oregon Health and Science University. The results will be converted to centile charts with the aid of a biostatistician. Centile charts will be used to track statistical changes over time in the following gait parameters including but not exclusive to: velocity, cadence, step length, and base of support.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01920828
|United States, Oregon|
|Oregon Health and Science University|
|Portland, Oregon, United States, 97239|